Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
Q4 2023 Biofrontera Inc Earnings Call
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Biofrontera Inc. (NASDAQ:BFRI): Is Breakeven Near?
Biofrontera Misses Q2 Top and Bottom Line Estimates; Reaffirms FY23 Outlook
Biofrontera Inc. Announces Voting Results From 2022 Annual Meeting of Stockholders
WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results
Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ:BFRI), announced today that they will be participating in Renmark Financial Communications Inc.'s live
Biofrontera Reports Q3 Earnings Beat; Updates FY22 Revenue Guidance Range
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications
Biofrontera Inc.'s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
Globe Newswire 6-Sep-2022 10:31 AMCompany also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols WOBURN, Mass.
Biofrontera Inc.'s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology
WOBURN, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in th
Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance
Biofrontera press release (NASDAQ:BFRI): Q2 GAAP EPS of -$0.05. Revenue of $4.5M (-23.7% Y/Y). As of June 30, 2022, Biofrontera Inc. had cash and cash equivalents of $31.9M, compared with $24.5M as of
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the comme
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has entered into agreements with certain of its holders of
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's Ameluz®
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Socie
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private p
No Data